Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Aristotle Small/Mid Cap Equity Jack McPherson and Dave Adams | “Haemonetics designs and manufactures medical devices and consumable equipment dedicated to blood processing, plasma collection, and surgical suite hematology management. The manager is bullish, viewing the business as an entrenched healthcare specialist benefiting from accelerating commercial execution and resilient underlying market demand. The company possesses a strong economic moat created by proprietary plasmapheresis systems and hospital-integrated blood management solutions. These platforms generate recurring consumable sales, expanding gross margins, and consistent free cash flow conversion. Reinvestment in internal research and development reinforces pricing power and insulates competitive market share. Primary catalysts include sustained plasma collection volume recoveries and new hospital product adoptions. Key risks center on potential regulatory hurdles, supply chain disruptions, or customer consolidation among major commercial plasma fractionators.” | BULL | Q3 2026 Oct 15, 2026 | View Pitch |
Riverwater Sustainable Value Strategy Adam J. Peck, CFA | “Haemonetics ($HAE) provides automated plasma collection systems, blood processing hardware, and specialized surgical interventional technologies. The manager's bullish stance is predicated on the company's entrenched global leadership in plasma collection and a re-acceleration in top-line growth following the unexpected return of its largest customer, CSL. From an economic standpoint, Haemonetics benefits from a classic 'razor-and-blade' business model characterized by proprietary hardware placements that generate recurring sales of high-margin single-use collection disposables. This recurring revenue structure yields substantial operating leverage, robust free cash flow conversion, and strong return on invested capital as collection volumes scale. Catalysts include contract ramp-ups and volume recovery from the CSL reinstatement alongside accelerated adoption of its interventional cardiology portfolio. Key risks include hospital capex reductions, plasma donor collection volatility, and customer concentration.” | BULL | Q3 2026 Oct 15, 2026 | View Pitch |
Ariel Small Cap Value Strategy Ariel Investments, LLC | “Haemonetics Corporation ($HAE), which represents 3.1% of the portfolio, designs and commercializes hematology devices, blood separation equipment, and specialized vascular closure solutions. Ariel is constructive on the company following quarterly outperformance and upward guidance adjustments. The manager's investment thesis highlights strengthening underlying operational execution and expanding market share in core plasma collection franchises. Financially, Haemonetics benefits from attractive unit economics and recurring revenue streams generated by high-margin proprietary consumables used with its donor collection devices. Operating margins continue to expand alongside robust free cash flow generation. The company's competitive moat was recently fortified by securing a significant multi-year supply agreement with CSL Plasma, providing long-term revenue visibility, expanding customer volume commitments, and elevating structural returns on capital. Upcoming catalysts involve the commercial rollout and volume ramp under the CSL Plasma agreement, paired with expanding adoption in the high-growth vascular closure business. Potential risks include regulatory approval timelines for new medical devices, collection center labor constraints, and potential customer concentration within the blood fractionation sector.” | BULL | Q3 2026 Oct 15, 2026 | View Pitch |
Ariel Appreciation Fund John W. Rogers | “Haemonetics Corporation ($HAE), constituting 2.7% of the fund, develops and distributes specialized hematology technologies, blood management products, and plasma collection solutions. The manager is bullish on the business due to its accelerating operational performance, market share gains in donor plasma collection, and an expanding commercial footprint across hospitals and specialized clinics. From an economic standpoint, Haemonetics operates an attractive recurring revenue model backed by strong pricing power and high customer switching costs in plasma fractionation centers. Operating leverage is driven by expanding production efficiency and robust cash flow conversion, which are further accelerated by high-margin consumables within its vascular closure business. A newly secured multi-year commercial supply agreement with CSL Plasma serves as a major commercial moat expansion, reinforcing long-term return on invested capital. Near-term catalysts include the revenue ramp from the CSL Plasma contract, continued volume recovery in plasma donations, and margin expansion across hospital specialties. Downside risks involve regulatory scrutiny around blood-handling protocols, unexpected disruptions in plasma donor velocity, and distributor integration frictions.” | BULL | Q3 2026 Oct 15, 2026 | View Pitch |
Ariel Appreciation Fund John W. Rogers | “Also during the quarter, we initiated a position in Haemonetics Corporation (HAE), a developer and distributor of a broad portfolio of hematology products and solutions. The company operates across three primary segments: Plasma, Blood Center and Hospital. The Plasma segment provides automated plasma collection systems and donor management software, while the Blood Center segment offers apheresis-based technologies that enable the collection, filtration and separation of blood components, returning remaining elements safely to the donor. The Hospital segment encompasses interventional technologies such as vascular closure devices and sensor-guided systems alongside comprehensive blood management solutions. With management's continued emphasis on life-sustaining healthcare applications, we believe Haemonetics stands to benefit from favorable demographic trends, rising demand for plasma-based therapies and continued innovation in critical care technologies.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Ariel Fund John W. Rogers, Jr. | “Also during the quarter, we initiated a position in Haemonetics Corporation (HAE), a developer and distributor of a broad portfolio of hematology products and solutions. The company operates across three primary segments: Plasma, Blood Center and Hospital. The Plasma segment provides automated plasma collection systems and donor management software, while the Blood Center segment offers apheresis-based technologies that enable the collection, filtration and separation of blood components, returning remaining elements safely to the donor. The Hospital segment encompasses interventional technologies such as vascular closure devices and sensor-guided systems alongside comprehensive blood management solutions. With management's continued emphasis on life-sustaining healthcare applications, we believe Haemonetics stands to benefit from favorable demographic trends, rising demand for plasma-based therapies and continued innovation in critical care technologies.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Ariel Small Cap Value Strategy Ariel Investments, LLC | “Also during the quarter, we initiated a position in Haemonetics Corporation (HAE), a developer and distributor of a broad portfolio of hematology products and solutions. The company operates across three primary segments: Plasma, Blood Center and Hospital. The Plasma segment provides automated plasma collection systems and donor management software, while the Blood Center segment offers apheresis-based technologies that enable the collection, filtration and separation of blood components, returning remaining elements safely to the donor. The Hospital segment encompasses interventional technologies such as vascular closure devices and sensor-guided systems alongside comprehensive blood management solutions. With management's continued emphasis on life-sustaining healthcare applications, we believe Haemonetics stands to benefit from favorable demographic trends, rising demand for plasma-based therapies and continued innovation in critical care technologies.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
The London Company Small Cap The London Company of Virginia, LLC | “HAE entered the quarter with very low expectations, which helped drive a strong stock reaction following earnings. Guidance increased due to improving margins from initiatives. HAE will likely reach its long-term margin targets outlined at its prior investor day. While some parts of the business are still improving, strength in other areas has helped offset those challenges. Buybacks increased at these depressed valuation prices, enhancing shareholder value. Overall, we believe the setup remains attractive, supported by the company's underlying quality. BSD Analysis: Haemonetics sells mission-critical blood management systems embedded in hospital workflows where switching risk is clinical, not financial. Demand is tied to procedures and transfusion needs, not elective consumer cycles. Once hospitals standardize on a platform, inertia is powerful. Investors worry about product cycles and reimbursement noise. Yet consumables and disposables drive recurring revenue. Innovation improves outcomes and efficiency rather than chasing novelty. Margins expand as scale and mix improve. This is healthcare infrastructure that quietly compounds.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Riverwater Sustainable Value Strategy Adam J. Peck, CFA | “Haemonetics Corporation (HAE) was the top contributor in the quarter. It was the worst performer during the 3rd quarter, when the stock sank 33% following a slightly disappointing second quarter report for its Hospital segment and lingering concern by some about the health of its plasma collections equipment business. We had high confidence that the plasma market was returning to its historic high-single-digit growth rate, and that HAE's Hospital portfolio has great potential; therefore, we added to our position. In November, HAE reported strong third quarter results in both its Hospital and Plasma segments, propelling the stock to recoup its prior losses and more. We believe these trends offer opportunities for HAE going forward. BSD Analysis: Haemonetics supplies blood and plasma collection technology with strong recurring consumables revenue. Plasma demand continues to rise structurally. Operational missteps hurt credibility, but core demand remains intact. Switching costs are high for collection centers. Margin recovery depends on execution, not TAM. Investors punished the stock aggressively. Stabilization alone would drive upside. This is a franchise repair story. Demand is not the issue.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.